CERo Therapeutics (CERO) via Phoenix Biotech (PBAX) deck
CERo is an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms. Its lead product candidate is expected to enter clinical trials in 2024.
![](/content/images/size/w1304/2023/06/g494471ex99_2s1g1-1.jpg)